Recap: ResMed Q2 Earnings
Portfolio Pulse from Benzinga Insights
ResMed (NYSE:RMD) reported Q2 earnings with an EPS of $1.88, beating estimates by 5.03% and surpassing last year's revenue by $129 million. Despite beating last quarter's EPS estimate, the share price fell by 2.94% the following day. ResMed has a history of mixed earnings performance over the past quarters.
January 24, 2024 | 9:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ResMed reported a positive Q2 earnings surprise with an EPS of $1.88, beating the estimate by 5.03% and showing a significant year-over-year revenue increase.
ResMed's positive earnings report, beating estimates and showing revenue growth, is likely to instill investor confidence and could lead to a short-term uptick in stock price. However, considering the stock price dropped after the last earnings beat, the market reaction might be tempered. The score reflects the positive earnings but is cautious due to past market reactions.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100